Rimadyl Palatable Tablets for Dogs 100 mg

Երկիր: Միացյալ Թագավորություն

Լեզու: անգլերեն

Աղբյուրը: VMD (Veterinary Medicines Directorate)

Ակտիվ բաղադրիչ:

Carprofen

Հասանելի է:

Zoetis UK Limited

ATC կոդը:

QM01AE91

INN (Միջազգային անվանումը):

Carprofen

Դեղագործական ձեւ:

Tablet

Ռեկվիզորի տեսակը:

POM-V - Prescription Only Medicine – Veterinarian

Թերապեւտիկ խումբ:

Dogs

Թերապեւտիկ տարածք:

Anti Inflammatory NSAID

Լիազորման կարգավիճակը:

Authorized

Հաստատման ամսաթիվը:

2003-02-14

Ապրանքի հատկությունները

Revised: April 2020
AN: 01995/2019
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl Palatable Tablets for dogs 100 mg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 100mg Carprofen.
For the full list of all other excipients see section 6.1
3.
PHARMACEUTICAL FORM
Tablet.
A light brown square tablet with “R” engraved on one side and
bisected on the
other side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For
analgesia
and
reduction
of
chronic
inflammation,
for
example
in
degenerative joint disease in the dog.
The tablets can also be used in the management of post-operative pain.
4.3
CONTRAINDICATIONS
Do not exceed the stated dose.
The elimination time of NSAIDs, including carprofen, in the cat is
longer than in
the dog and the therapeutic index is narrower. In the absence of
specific data
use in the cat is contra-indicated.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there
is a possibility of gastro-intestinal ulceration or bleeding, or where
there is
evidence of blood dyscrasia or hypersensitivity to the product. As
with other
NSAIDs there is a risk of rare idiosyncratic renal or hepatic adverse
events.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Some NSAIDs may be highly bound to plasma proteins and compete with
other
highly bound drugs, which can lead to toxic effects.
Revised: April 2020
AN: 01995/2019
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
i) Special precautions for use in animals
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional
risk. If such a use cannot be avoided, such dogs may require a reduced
dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential rise of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAID’s can cause inhibiti